New Vernon Capital Holdings II LLC Invests $122,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

New Vernon Capital Holdings II LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,822 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $65,000. KBC Group NV boosted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $134,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CPRX. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Stock Up 0.3 %

Catalyst Pharmaceuticals stock opened at $23.19 on Friday. The stock has a market capitalization of $2.83 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The company has a 50 day moving average of $22.57 and a 200-day moving average of $22.16.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.